close 74% van de retail beleggers lijdt verlies op de handel in CFD`s met deze aanbieder. Investeringen brengen risico`s met zich mee en zijn niet geschikt voor alle beleggers. CFD`s zijn complexe instrumenten met een hoog risico om snel gelden te verliezen vanwege het hefboomeffect. 74% van de retail beleggers lijdt verlies op de handel in CFD`s met deze aanbieder. Het is belangrijk dat u goed begrijpt hoe CFD`s werken en dat u nagaat of u zich het hoge risico op verlies kunt permitteren.
ZoekenZoeken
Change languageNederlands
Dashboard

LLY

901.88

-1.61%↓

JNJ

234.69

-0.14%↓

ABBV

205.2

+0.86%↑

NVS

148.44

+0.64%↑

AZN

184.61

+0.29%↑

LLY

901.88

-1.61%↓

JNJ

234.69

-0.14%↓

ABBV

205.2

+0.86%↑

NVS

148.44

+0.64%↑

AZN

184.61

+0.29%↑

LLY

901.88

-1.61%↓

JNJ

234.69

-0.14%↓

ABBV

205.2

+0.86%↑

NVS

148.44

+0.64%↑

AZN

184.61

+0.29%↑

LLY

901.88

-1.61%↓

JNJ

234.69

-0.14%↓

ABBV

205.2

+0.86%↑

NVS

148.44

+0.64%↑

AZN

184.61

+0.29%↑

LLY

901.88

-1.61%↓

JNJ

234.69

-0.14%↓

ABBV

205.2

+0.86%↑

NVS

148.44

+0.64%↑

AZN

184.61

+0.29%↑

Home・Aandelen Lijst・MiNK Therapeutics
Search

MiNK Therapeutics

Open

8.65 -1.03

Buy

Prijsupdate 24 mrt 2026, 16:35 UTC

BuySell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

8.43

Max

8.92

Belangrijke statistieken

By Trading Economics

Inkomsten

1.4M

-2.9M

EPS

-0.65

Werknemers

23

EBITDA

1.3M

-2.8M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+271.94% upside

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-19M

43M

Vorige openingsprijs

9.68

Vorige sluitingsprijs

8.65

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

7.81 / 8.1 Steun & Weerstand

MiNK Therapeutics Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

23 mrt 2026, 23:47 UTC

Acquisities, Fusies, Overnames

Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets -- Update

DJ

Lezen

23 mrt 2026, 22:55 UTC

Acquisities, Fusies, Overnames

Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion

DJ

Lezen

23 mrt 2026, 21:51 UTC

Acquisities, Fusies, Overnames

Italy's Postal Service Makes $12.50 Billion Bid for Telecom Italia -- 3rd Update

DJ

Lezen

23 mrt 2026, 23:59 UTC

Marktinformatie

Global Equities Roundup: Market Talk

DJ

Lezen

23 mrt 2026, 23:59 UTC

Marktinformatie

Woodside, Santos Earnings Power Up on Surging LNG Prices -- Market Talk

DJ

Lezen

23 mrt 2026, 23:50 UTC

Marktinformatie

Nikkei May Rise on Hopes for U.S. Talks With Iran -- Market Talk

DJ

Lezen

23 mrt 2026, 23:37 UTC

Marktinformatie

Gold Rises, Boosted by Fall in Dollar, U.S. Treasury Yields -- Market Talk

DJ

Lezen

23 mrt 2026, 22:42 UTC

Marktinformatie
Belangrijke Nieuwsgebeurtenissen

Global Equities Roundup: Market Talk

DJ

Lezen

23 mrt 2026, 22:42 UTC

Marktinformatie
Belangrijke Nieuwsgebeurtenissen

Bell Potter Names Miners Less Exposed to Fuel Price, Supply Risks -- Market Talk

DJ

Lezen

23 mrt 2026, 22:40 UTC

Acquisities, Fusies, Overnames

Gilead Sciences to Buy Ouro Medicines for Up to $2.18B

DJ

Lezen

23 mrt 2026, 22:23 UTC

Marktinformatie

Apollo Debt Solutions Shrugs Off Private-Credit Fears -- Market Talk

DJ

Lezen

23 mrt 2026, 22:22 UTC

Acquisities, Fusies, Overnames

Gilead Sciences: OM336 Is for Treatment of Autoantibodies Driven Immune-Mediated Disease

DJ

Lezen

23 mrt 2026, 22:21 UTC

Acquisities, Fusies, Overnames

Gilead Sciences: Company Would Pay Galapagos Royalties of 20%-23% of Net OM336 Sales

DJ

Lezen

23 mrt 2026, 22:21 UTC

Acquisities, Fusies, Overnames

Gilead Sciences: Company Would Retain Sole Worldwide Commercialization Rights of OM336 Outside of Greater China

DJ

Lezen

23 mrt 2026, 22:20 UTC

Acquisities, Fusies, Overnames

Gilead Sciences: Company, Galapagos Would Collaborate on Development of OM336 >GILD

DJ

Lezen

23 mrt 2026, 22:20 UTC

Acquisities, Fusies, Overnames

Gilead Sciences: Galapagos Would Absorb Substantially All of Ouro's Operating Assets, Retain Its Employees >GILD

DJ

Lezen

23 mrt 2026, 22:19 UTC

Acquisities, Fusies, Overnames

Gilead Sciences: Galapagos Would Pay 50% of Upfront Consideration and 50% of Any Contingent Milestone Payments Payable to Ouro Shareholders

DJ

Lezen

23 mrt 2026, 22:19 UTC

Acquisities, Fusies, Overnames

Gilead Sciences: Currently in Advanced Discussions With Galapagos With Respect to Potential Research-and-Development Collaboration on Acquired Ouro Assets

DJ

Lezen

23 mrt 2026, 22:18 UTC

Acquisities, Fusies, Overnames

Gilead Sciences to Buy Ouro Medicines for About $1.68B Upfront, Up to $500M in Contingent Milestone Payments >GILD

DJ

Lezen

23 mrt 2026, 22:15 UTC

Acquisities, Fusies, Overnames

Gilead Sciences To Acquire Ouro Medicines To Advance First In Class T Cell Engager Program For Autoimmune Diseases >GILD

DJ

Lezen

23 mrt 2026, 22:08 UTC

Marktinformatie

Ebos Needs to Reset Its Gearing Targets -- Market Talk

DJ

Lezen

23 mrt 2026, 21:42 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

DJ

Lezen

23 mrt 2026, 21:42 UTC

Marktinformatie

RBNZ's Breman Strikes Reassuring Tone On Rates -- Market Talk

DJ

Lezen

23 mrt 2026, 21:32 UTC

Winsten

WuXi XDC Cayman: Results Aided by Strong Growth in Contract Research, Development and Manufacturing Organisation Business>2268.HK

DJ

Lezen

23 mrt 2026, 21:32 UTC

Winsten

WuXi XDC Cayman 2025 Net CNY1.56B Vs. Net CNY917.16M >2268.HK

DJ

Lezen

23 mrt 2026, 21:32 UTC

Winsten

WuXi XDC Cayman 2025 Rev CNY5.94B Vs. CNY4.05B >2268.HK

DJ

Lezen

23 mrt 2026, 21:10 UTC

Belangrijke Nieuwsgebeurtenissen

Oil Is Back Under $100. Trump Says Iran Has Agreed to No Nuclear Weapons. -- Barrons.com

DJ

Lezen

23 mrt 2026, 20:50 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

DJ

Lezen

23 mrt 2026, 20:50 UTC

Marktinformatie

Health Care Roundup: Market Talk

DJ

Lezen

23 mrt 2026, 20:50 UTC

Marktinformatie
Winsten
Belangrijke Nieuwsgebeurtenissen

Basic Materials Roundup: Market Talk

DJ

Lezen

Peer Vergelijking

Prijswijziging

MiNK Therapeutics Prognose

Koersdoel

By TipRanks

271.94% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 35 USD  271.94%

Hoogste 35 USD

Laagste 35 USD

Gebaseerd op 1 Wall Street-analisten die 12-maands prijsdoelen bieden voor MiNK Therapeutics - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

1 ratings

1

Buy

0

Hold

0

Sell

Gebaseerd op 1 analisten die aandelenratings hebben gegeven aan MiNK Therapeutics - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

7.81 / 8.1Steun & Weerstand

Korte Termijn

Bullish Evidence

Recent bullish events outweigh bearish events.

Gemiddeld Termijn

Bullish Evidence

Recent bullish events outweigh bearish events.

Lange Termijn

Bearish Evidence

There is one bearish event.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Andere aandelen uit de sector

LLY

Eli Lilly and Co.

901.88

↓-1.61%

JNJ

Johnson and Johnson

234.69

↓-0.14%

ABBV

AbbVie Inc

205.2

↑ +0.86%

NVS

Novartis AG

148.44

↑ +0.64%

AZN

AstraZeneca PLC

184.61

↑ +0.29%
help-icon Live chat